Global Verapamil Market

Verapamil Comprehensive Study by Route of Administration (Oral, Injectable), Form (Tablets, Injection, Capsules), Distribution Channel (Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Verapamil Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Verapamil is a calcium channel blocker medicine that is used to treat high blood pressure, angina, and supraventricular tachycardia. It is available under a variety of brand names. Migraines and cluster headaches can also be prevented with this supplement. It can be taken orally or injected into a vein. It works by relaxing blood arteries, allowing the heart to pump more efficiently. To manage the heart rate, it also enhances the supply of blood and oxygen to the heart and lowers electrical activity in the heart. The market is expected to grow as people have become more health conscious. Moreover increase in geriatric population coupled with increasing cases of high blood pressure etc is expected to boost the market.This growth is primarily driven by Increase in Geriatric Population and Growing Spending by People on Healthcare.

Globally, a noticeable market trend is evident Growing Cases of High Blood Pressure and Other Diseases. Major Players, such as Zydus Cadila (India), Pfizer (United States), Abbott Laboratories (United States), Mylan(United States), AbbVie(United States), Merck & Co(United States), Sanofi (France), Teva (Israel), Novartis (Switzerland) and Sun Pharma (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

October 2020 – Drug firm Zydus Cadila on Announced it has received final approval from the US health regulator to market Fingolimod capsules and Verapamil Hydrochloride Injection. Verapamil Hydrochloride Injection is used to rapidly/temporarily restore normal heartbeats in people with certain heart rhythm disorders.

Market Drivers
  • Increase in Geriatric Population
  • Growing Spending by People on Healthcare

Market Trend
  • Growing Cases of High Blood Pressure and Other Diseases

Restraints
  • Stringent Regulatory Factors

Opportunities
Growing Research and Development Activities and Rising Investment in Healthcare Industry
Challenges
High Cost of Treatment

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Verapamil Study Sheds Light on
— The Verapamil Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Verapamil industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Verapamil industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Route of Administration
  • Oral
  • Injectable

By Form
  • Tablets
  • Injection
  • Capsules

By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Geriatric Population
      • 3.2.2. Growing Spending by People on Healthcare
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Treatment
    • 3.4. Market Trends
      • 3.4.1. Growing Cases of High Blood Pressure and Other Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Verapamil, by Route of Administration, Form, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Verapamil (Value)
      • 5.2.1. Global Verapamil by: Route of Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Injectable
      • 5.2.2. Global Verapamil by: Form (Value)
        • 5.2.2.1. Tablets
        • 5.2.2.2. Injection
        • 5.2.2.3. Capsules
      • 5.2.3. Global Verapamil by: Distribution Channel (Value)
        • 5.2.3.1. Retail Pharmacies
        • 5.2.3.2. Online Pharmacies
      • 5.2.4. Global Verapamil Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Verapamil: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Zydus Cadila (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sun Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Verapamil Sale, by Route of Administration, Form, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Verapamil (Value)
      • 7.2.1. Global Verapamil by: Route of Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Injectable
      • 7.2.2. Global Verapamil by: Form (Value)
        • 7.2.2.1. Tablets
        • 7.2.2.2. Injection
        • 7.2.2.3. Capsules
      • 7.2.3. Global Verapamil by: Distribution Channel (Value)
        • 7.2.3.1. Retail Pharmacies
        • 7.2.3.2. Online Pharmacies
      • 7.2.4. Global Verapamil Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Verapamil: by Route of Administration(USD Million)
  • Table 2. Verapamil Oral , by Region USD Million (2015-2020)
  • Table 3. Verapamil Injectable , by Region USD Million (2015-2020)
  • Table 4. Verapamil: by Form(USD Million)
  • Table 5. Verapamil Tablets , by Region USD Million (2015-2020)
  • Table 6. Verapamil Injection , by Region USD Million (2015-2020)
  • Table 7. Verapamil Capsules , by Region USD Million (2015-2020)
  • Table 8. Verapamil: by Distribution Channel(USD Million)
  • Table 9. Verapamil Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 10. Verapamil Online Pharmacies , by Region USD Million (2015-2020)
  • Table 11. South America Verapamil, by Country USD Million (2015-2020)
  • Table 12. South America Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 13. South America Verapamil, by Form USD Million (2015-2020)
  • Table 14. South America Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 15. Brazil Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 16. Brazil Verapamil, by Form USD Million (2015-2020)
  • Table 17. Brazil Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 18. Argentina Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 19. Argentina Verapamil, by Form USD Million (2015-2020)
  • Table 20. Argentina Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 21. Rest of South America Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 22. Rest of South America Verapamil, by Form USD Million (2015-2020)
  • Table 23. Rest of South America Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 24. Asia Pacific Verapamil, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 26. Asia Pacific Verapamil, by Form USD Million (2015-2020)
  • Table 27. Asia Pacific Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 28. China Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 29. China Verapamil, by Form USD Million (2015-2020)
  • Table 30. China Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 31. Japan Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 32. Japan Verapamil, by Form USD Million (2015-2020)
  • Table 33. Japan Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 34. India Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 35. India Verapamil, by Form USD Million (2015-2020)
  • Table 36. India Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 37. South Korea Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 38. South Korea Verapamil, by Form USD Million (2015-2020)
  • Table 39. South Korea Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 40. Taiwan Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 41. Taiwan Verapamil, by Form USD Million (2015-2020)
  • Table 42. Taiwan Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 43. Australia Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 44. Australia Verapamil, by Form USD Million (2015-2020)
  • Table 45. Australia Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Verapamil, by Form USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 49. Europe Verapamil, by Country USD Million (2015-2020)
  • Table 50. Europe Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 51. Europe Verapamil, by Form USD Million (2015-2020)
  • Table 52. Europe Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 53. Germany Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 54. Germany Verapamil, by Form USD Million (2015-2020)
  • Table 55. Germany Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 56. France Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 57. France Verapamil, by Form USD Million (2015-2020)
  • Table 58. France Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 59. Italy Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 60. Italy Verapamil, by Form USD Million (2015-2020)
  • Table 61. Italy Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 62. United Kingdom Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 63. United Kingdom Verapamil, by Form USD Million (2015-2020)
  • Table 64. United Kingdom Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 65. Netherlands Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 66. Netherlands Verapamil, by Form USD Million (2015-2020)
  • Table 67. Netherlands Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 68. Rest of Europe Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 69. Rest of Europe Verapamil, by Form USD Million (2015-2020)
  • Table 70. Rest of Europe Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 71. MEA Verapamil, by Country USD Million (2015-2020)
  • Table 72. MEA Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 73. MEA Verapamil, by Form USD Million (2015-2020)
  • Table 74. MEA Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 75. Middle East Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 76. Middle East Verapamil, by Form USD Million (2015-2020)
  • Table 77. Middle East Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 78. Africa Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 79. Africa Verapamil, by Form USD Million (2015-2020)
  • Table 80. Africa Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 81. North America Verapamil, by Country USD Million (2015-2020)
  • Table 82. North America Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 83. North America Verapamil, by Form USD Million (2015-2020)
  • Table 84. North America Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 85. United States Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 86. United States Verapamil, by Form USD Million (2015-2020)
  • Table 87. United States Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 88. Canada Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 89. Canada Verapamil, by Form USD Million (2015-2020)
  • Table 90. Canada Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 91. Mexico Verapamil, by Route of Administration USD Million (2015-2020)
  • Table 92. Mexico Verapamil, by Form USD Million (2015-2020)
  • Table 93. Mexico Verapamil, by Distribution Channel USD Million (2015-2020)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Verapamil: by Route of Administration(USD Million)
  • Table 105. Verapamil Oral , by Region USD Million (2021-2026)
  • Table 106. Verapamil Injectable , by Region USD Million (2021-2026)
  • Table 107. Verapamil: by Form(USD Million)
  • Table 108. Verapamil Tablets , by Region USD Million (2021-2026)
  • Table 109. Verapamil Injection , by Region USD Million (2021-2026)
  • Table 110. Verapamil Capsules , by Region USD Million (2021-2026)
  • Table 111. Verapamil: by Distribution Channel(USD Million)
  • Table 112. Verapamil Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 113. Verapamil Online Pharmacies , by Region USD Million (2021-2026)
  • Table 114. South America Verapamil, by Country USD Million (2021-2026)
  • Table 115. South America Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 116. South America Verapamil, by Form USD Million (2021-2026)
  • Table 117. South America Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 118. Brazil Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 119. Brazil Verapamil, by Form USD Million (2021-2026)
  • Table 120. Brazil Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 121. Argentina Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 122. Argentina Verapamil, by Form USD Million (2021-2026)
  • Table 123. Argentina Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 124. Rest of South America Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 125. Rest of South America Verapamil, by Form USD Million (2021-2026)
  • Table 126. Rest of South America Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 127. Asia Pacific Verapamil, by Country USD Million (2021-2026)
  • Table 128. Asia Pacific Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 129. Asia Pacific Verapamil, by Form USD Million (2021-2026)
  • Table 130. Asia Pacific Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 131. China Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 132. China Verapamil, by Form USD Million (2021-2026)
  • Table 133. China Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 134. Japan Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 135. Japan Verapamil, by Form USD Million (2021-2026)
  • Table 136. Japan Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 137. India Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 138. India Verapamil, by Form USD Million (2021-2026)
  • Table 139. India Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 140. South Korea Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 141. South Korea Verapamil, by Form USD Million (2021-2026)
  • Table 142. South Korea Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 143. Taiwan Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 144. Taiwan Verapamil, by Form USD Million (2021-2026)
  • Table 145. Taiwan Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 146. Australia Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 147. Australia Verapamil, by Form USD Million (2021-2026)
  • Table 148. Australia Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Verapamil, by Form USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 152. Europe Verapamil, by Country USD Million (2021-2026)
  • Table 153. Europe Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 154. Europe Verapamil, by Form USD Million (2021-2026)
  • Table 155. Europe Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 156. Germany Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 157. Germany Verapamil, by Form USD Million (2021-2026)
  • Table 158. Germany Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 159. France Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 160. France Verapamil, by Form USD Million (2021-2026)
  • Table 161. France Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 162. Italy Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 163. Italy Verapamil, by Form USD Million (2021-2026)
  • Table 164. Italy Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 165. United Kingdom Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 166. United Kingdom Verapamil, by Form USD Million (2021-2026)
  • Table 167. United Kingdom Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 168. Netherlands Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 169. Netherlands Verapamil, by Form USD Million (2021-2026)
  • Table 170. Netherlands Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 171. Rest of Europe Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 172. Rest of Europe Verapamil, by Form USD Million (2021-2026)
  • Table 173. Rest of Europe Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 174. MEA Verapamil, by Country USD Million (2021-2026)
  • Table 175. MEA Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 176. MEA Verapamil, by Form USD Million (2021-2026)
  • Table 177. MEA Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 178. Middle East Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 179. Middle East Verapamil, by Form USD Million (2021-2026)
  • Table 180. Middle East Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 181. Africa Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 182. Africa Verapamil, by Form USD Million (2021-2026)
  • Table 183. Africa Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 184. North America Verapamil, by Country USD Million (2021-2026)
  • Table 185. North America Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 186. North America Verapamil, by Form USD Million (2021-2026)
  • Table 187. North America Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 188. United States Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 189. United States Verapamil, by Form USD Million (2021-2026)
  • Table 190. United States Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 191. Canada Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 192. Canada Verapamil, by Form USD Million (2021-2026)
  • Table 193. Canada Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 194. Mexico Verapamil, by Route of Administration USD Million (2021-2026)
  • Table 195. Mexico Verapamil, by Form USD Million (2021-2026)
  • Table 196. Mexico Verapamil, by Distribution Channel USD Million (2021-2026)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Verapamil: by Route of Administration USD Million (2015-2020)
  • Figure 5. Global Verapamil: by Form USD Million (2015-2020)
  • Figure 6. Global Verapamil: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Verapamil Share (%), by Country
  • Figure 8. Asia Pacific Verapamil Share (%), by Country
  • Figure 9. Europe Verapamil Share (%), by Country
  • Figure 10. MEA Verapamil Share (%), by Country
  • Figure 11. North America Verapamil Share (%), by Country
  • Figure 12. Global Verapamil share by Players 2020 (%)
  • Figure 13. Global Verapamil share by Players (Top 3) 2020(%)
  • Figure 14. Global Verapamil share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Zydus Cadila (India) Revenue, Net Income and Gross profit
  • Figure 17. Zydus Cadila (India) Revenue: by Geography 2020
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2020
  • Figure 20. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 22. Mylan(United States) Revenue, Net Income and Gross profit
  • Figure 23. Mylan(United States) Revenue: by Geography 2020
  • Figure 24. AbbVie(United States) Revenue, Net Income and Gross profit
  • Figure 25. AbbVie(United States) Revenue: by Geography 2020
  • Figure 26. Merck & Co(United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co(United States) Revenue: by Geography 2020
  • Figure 28. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi (France) Revenue: by Geography 2020
  • Figure 30. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 31. Teva (Israel) Revenue: by Geography 2020
  • Figure 32. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 34. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 35. Sun Pharma (India) Revenue: by Geography 2020
  • Figure 36. Global Verapamil: by Route of Administration USD Million (2021-2026)
  • Figure 37. Global Verapamil: by Form USD Million (2021-2026)
  • Figure 38. Global Verapamil: by Distribution Channel USD Million (2021-2026)
  • Figure 39. South America Verapamil Share (%), by Country
  • Figure 40. Asia Pacific Verapamil Share (%), by Country
  • Figure 41. Europe Verapamil Share (%), by Country
  • Figure 42. MEA Verapamil Share (%), by Country
  • Figure 43. North America Verapamil Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Zydus Cadila (India)
  • Pfizer (United States)
  • Abbott Laboratories (United States)
  • Mylan(United States)
  • AbbVie(United States)
  • Merck & Co(United States)
  • Sanofi (France)
  • Teva (Israel)
  • Novartis (Switzerland)
  • Sun Pharma (India)
Additional players considered in the study are as follows:
Recro Gainesville (United States) , Array BioPharma (United States)
Select User Access Type

Key Highlights of Report


Jun 2021 233 Pages 92 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Verapamil Market Quantitative research analysis
Global Verapamil Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Verapamil market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Verapamil market are Zydus Cadila (India), Pfizer (United States), Abbott Laboratories (United States), Mylan(United States), AbbVie(United States), Merck & Co(United States), Sanofi (France), Teva (Israel), Novartis (Switzerland) and Sun Pharma (India), to name a few.
is dominating the Verapamil Market.

Know More About Global Verapamil Market Report?

Have a Query? Click Here

Other Related Reports

Penicillamine Comprehensive Study by Type (Penicillamine Capsule, Penicillamine Tablet), Application (Wilson's disease, Arsenic poisoning, Rheumatoid arthritis), End User (Hospitals, Clinics, Others)...
$ 3500
Seasickness Medicine Comprehensive Study by Type (Anticholinergic, Antihistamines), Route of Administration (Oral, Transdermal, Parenteral, Other), Distribution Channel (Retail Pharmacies, Online Pha...
$ 3500
Airsickness Treatment Comprehensive Study by Application (Adults, Children), Type (Anticholinergic, Antihistamines, Other), Treatment (Medication, Non-Medication, Others), Route of Administration (Or...
$ 3650
Dydrogesterone Drug Comprehensive Study by Type (Dydrogesterone, Dydrogesterone+Estradiol Compound), Application (Infertility, Gynecological Diseases, Threatened Abortion, Other), Distribution Channe...
$ 3800
Buckwheat Extract Comprehensive Study by Application (Food Supplements, Nutraceuticals Formulations, Dietary Supplements, Cosmeceuticals), Consumption (External, Internal), Form (Capsule, Tablet, Liq...
$ 3650
Biapenem Comprehensive Study by Type (150mg, 300mg, 600mg), Application (Sepsis, Pneumonia, Lung Abscess, Refractory Cystitis, Pyelonephritis, Peritonitis, Gynecologic Adnexitis), Sales Channel (Onli...
$ 3500